These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24828664)

  • 1. TGM2: a cell surface marker in esophageal adenocarcinomas.
    Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
    J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.
    Singhal S; Kapoor H; Subramanian S; Agrawal DK; Mittal SK
    J Gastrointest Cancer; 2019 Dec; 50(4):867-878. PubMed ID: 30187205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.
    Lockwood WW; Thu KL; Lin L; Pikor LA; Chari R; Lam WL; Beer DG
    Clin Cancer Res; 2012 Apr; 18(7):1936-46. PubMed ID: 22328562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.
    Blum AE; Venkitachalam S; Ravillah D; Chelluboyina AK; Kieber-Emmons AM; Ravi L; Kresak A; Chandar AK; Markowitz SD; Canto MI; Wang JS; Shaheen NJ; Guo Y; Shyr Y; Willis JE; Chak A; Varadan V; Guda K
    Gastroenterology; 2019 May; 156(6):1761-1774. PubMed ID: 30768984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
    Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
    Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?
    von Rahden BH; Kircher S; Lazariotou M; Reiber C; Stuermer L; Otto C; Germer CT; Grimm M
    J Exp Clin Cancer Res; 2011 Feb; 30(1):23. PubMed ID: 21345220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas.
    Ferrer-Torres D; Nancarrow DJ; Kuick R; Thomas DG; Nadal E; Lin J; Chang AC; Reddy RM; Orringer MB; Taylor JM; Wang TD; Beer DG
    Oncotarget; 2016 Aug; 7(34):54867-54882. PubMed ID: 27363029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.
    Silvers AL; Lin L; Bass AJ; Chen G; Wang Z; Thomas DG; Lin J; Giordano TJ; Orringer MB; Beer DG; Chang AC
    Clin Cancer Res; 2010 Apr; 16(7):2009-21. PubMed ID: 20332323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
    Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
    Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.
    Zhou Z; Bandla S; Ye J; Xia Y; Que J; Luketich JD; Pennathur A; Peters JH; Tan D; Godfrey TE
    BMC Gastroenterol; 2014 Apr; 14():78. PubMed ID: 24742107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic biomarkers in esophageal cancer.
    Kaz AM; Grady WM
    Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.